Helix BioPharma closes $16.9 million private placement of common shares

About this update from Helix Biopharma Corp.

[{"type":"text","content":"\n\n\n\nAURORA, ON, Dec. 19 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today\nannounced the closing of its previously announced private placement, for gross\nproceeds of CDN$16,867,200.\n\n\nAbout Helix BioPharma Corp.\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich\nand Stuttgart Stock Exchanges under the same symbol.\n\n\nThe Toronto Stock Exchange has not reviewed and does not accept\nresponsibility for the adequacy or accuracy of the content of this News\nRelease. This News Release contains forward-looking statements regarding a\nproposed private placement and the Company's activities, which statements can\nbe identified by the words "will", "anticipates", and "developing". Actual\nresults or events could differ materially from these forward-looking\nstatements due to numerous factors, including without limitation, the risk\nthat the proposed placement may not close as anticipated or at all, research &\ndevelopment risks, Helix's need for additional future capital, the risk of\nunanticipated expenses, and possible changes in business strategy or plans.\nThese and other risks and uncertainties are contained in Helix's latest Annual\nInformation Form at www.sedar.com. Forward-looking statements and information\nare based on the assumptions and expectations of Helix's management at the\ntime they are made, and Helix does not assume any obligation, except as\nrequired by law, to update any forward-looking statement or information should\nthose assumptions or expectations, or other circumstances change.\n\n\n","length":2037,"tagName":"div"}]

More updates from Helix Biopharma Corp.